Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06299761 · ClinicalTrials.gov registry record · Phase 1
Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications
A Phase 1 study, sponsored by Boundless Bio.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT06299761 is a Phase 1 study that was terminated before completion, run by Boundless Bio. The registered enrollment target is 19 participants.
The verdict
NCT06299761, a Phase 1 study, was terminated before completion, sponsored by Boundless Bio.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered as a single agent and in combination with select targeted therapies.
Interventions
- DRUG BBI-825
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2025-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06299761
The ClinicalTrials.gov registry entry for NCT06299761 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boundless Bio, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BBI-825 is the first listed.
NCT06299761 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06299761 about?
NCT06299761 is a clinical study titled "Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications". BBI-825 is a potent, selective, oral, small molecule inhibitor of ribonucleotide reductase (RNR). This is a first-in-human, open-label, non-randomized, 3-part, Phase 1/2 study to determine the safety profile and identify the maximum tolerated dose and recommended Phase 2 dose of BBI-825 administered...
What is the current status of trial NCT06299761?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2024-03-28. Estimated completion is 2025-06-25.
What interventions are being tested in trial NCT06299761?
The interventions under investigation include: BBI-825 (DRUG).
Who is sponsoring clinical trial NCT06299761?
This trial is sponsored by Boundless Bio, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.